Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atomoxetine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 91.44 mg (equivalent: atomoxetine, qty 80 mg) - capsule, hard - excipient ingredients: croscarmellose sodium; iron oxide red; iron oxide black; gelatin; iron oxide yellow; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; ethanol; shellac; sulfuric acid - atomoxetine ch is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 28.575 mg (equivalent: atomoxetine, qty 25 mg) - capsule, hard - excipient ingredients: titanium dioxide; gelatin; magnesium stearate; indigo carmine; pregelatinised maize starch; croscarmellose sodium; colloidal anhydrous silica; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - atomoxetine genpar is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 91.44 mg (equivalent: atomoxetine, qty 80 mg) - capsule, hard - excipient ingredients: iron oxide black; pregelatinised maize starch; gelatin; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; iron oxide red; iron oxide yellow; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; ethanol; shellac; sulfuric acid - atomoxetine an is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.